Literature DB >> 26896317

Preparation, Characterization, and Optimization of Folic Acid-Chitosan-Methotrexate Core-Shell Nanoparticles by Box-Behnken Design for Tumor-Targeted Drug Delivery.

Hamid Reza Naghibi Beidokhti1, Reza Ghaffarzadegan2, Sasan Mirzakhanlouei2, Leila Ghazizadeh3, Farid Abedin Dorkoosh4,5.   

Abstract

The objective of this study was to investigate the combined influence of independent variables in the preparation of folic acid-chitosan-methotrexate nanoparticles (FA-Chi-MTX NPs). These NPs were designed and prepared for targeted drug delivery in tumor. The NPs of each batch were prepared by coaxial electrospray atomization method and evaluated for particle size (PS) and particle size distribution (PSD). The independent variables were selected to be concentration of FA-chitosan, ratio of shell solution flow rate to core solution flow rate, and applied voltage. The process design of experiments (DOE) was obtained with three factors in three levels by Design expert software. Box-Behnken design was used to select 15 batches of experiments randomly. The chemical structure of FA-chitosan was examined by FTIR. The NPs of each batch were collected separately, and morphologies of NPs were investigated by field emission scanning electron microscope (FE-SEM). The captured pictures of all batches were analyzed by ImageJ software. Mean PS and PSD were calculated for each batch. Polynomial equation was produced for each response. The FE-SEM results showed the mean diameter of the core-shell NPs was around 304 nm, and nearly 30% of the produced NPs are in the desirable range. Optimum formulations were selected. The validation of DOE optimization results showed errors around 2.5 and 2.3% for PS and PSD, respectively. Moreover, the feasibility of using prepared NPs to target tumor extracellular pH was shown, as drug release was greater in the pH of endosome (acidic medium). Finally, our results proved that FA-Chi-MTX NPs were active against the human epithelial cervical cancer (HeLa) cells.

Entities:  

Keywords:  box-Behnken design; coaxial electrospray; folic acid-chitosan nanoparticles; methotrexate; optimization

Mesh:

Substances:

Year:  2016        PMID: 26896317     DOI: 10.1208/s12249-015-0445-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  6 in total

1.  Fabrication, characterization and optimization of berberine-loaded PLA nanoparticles using coaxial electrospray for sustained drug release.

Authors:  Reza Ghaffarzadegan; Sepideh Khoee; Shamsali Rezazadeh
Journal:  Daru       Date:  2020-04-20       Impact factor: 3.117

Review 2.  Recent Advances in Chitosan and its Derivatives in Cancer Treatment.

Authors:  Jingxian Ding; Yonghong Guo
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

3.  Production and Characterization of Chitosan-Polyanion Nanoparticles by Polyelectrolyte Complexation Assisted by High-Intensity Sonication for the Modified Release of Methotrexate.

Authors:  Yhors Ciro; John Rojas; Maria J Alhajj; Gustavo A Carabali; Constain H Salamanca
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-08

Review 4.  Layer-by-Layer Cell Encapsulation for Drug Delivery: The History, Technique Basis, and Applications.

Authors:  Wenyan Li; Xuejiao Lei; Hua Feng; Bingyun Li; Jiming Kong; Malcolm Xing
Journal:  Pharmaceutics       Date:  2022-01-27       Impact factor: 6.321

5.  Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.

Authors:  Amirhosein Kefayat; Maryam Hosseini; Fatemeh Ghahremani; Nafise Arbab Jolfaie; Mohammad Rafienia
Journal:  J Nanobiotechnology       Date:  2022-03-31       Impact factor: 10.435

6.  A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine.

Authors:  Ye Bi; Bingcong Lv; Lianlian Li; Robert J Lee; Jing Xie; Zhidong Qiu; Lesheng Teng
Journal:  Molecules       Date:  2020-01-14       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.